87 results
6-K
EX-99.3
AMYT
Amryt Pharma Plc
1 Jul 22
Posting of Annual Report and Notice of AGM
6:00am
and first presentation of open-label extension (OLE) data from 2nd year of OPTIMAL demonstrate the long-term safety and efficacy profile of Mycapssa® … support the long-term safety and efficacy of Mycapssa® in acromegaly patients who were previously biochemically controlled on monthly injectable
6-K
EX-99.2
AMYT
Amryt Pharma Plc
4 Aug 22
Results of Annual General Meeting
7:38am
and safety study of Oleogel-S10 (birch triterpenes) in patients with inherited EB, followed by a 24-month open-label single-arm phase. Analyses … in wound burden with a continued reassuring safety profile
Dr Tracy Cunningham, Chief Medical Officer of Amryt, commented: “We are pleased to present new
6-K
EX-99.4
AMYT
Amryt Pharma Plc
31 Jan 22
Current report (foreign)
7:32am
EXHIBIT 99.4
Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management … compliance rate of 99%.
- The long-term safety profile of Mycapssa® during the OLE was consistent with that observed in prior studies.
DUBLIN
6-K
EX-99.3
AMYT
Amryt Pharma Plc
11 May 22
Current report (foreign)
4:30pm
EXHIBIT 99.3
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label … of the OLE were 0.79 and 0.45 respectively)
Long-term safety profile of Mycapssa® during the OLE was consistent with that observed in prior studies
DUBLIN
6-K
EX-99.3
AMYT
Amryt Pharma Plc
31 Mar 22
Results of General Meeting
8:41am
at least 15 months of treatment with Oleogel-S10 ��
No new safety signals observed
DUBLIN, Ireland, and Boston MA, March 26, 2022, Amryt (Nasdaq: AMYT … -label phase (OLP) (n=205) from the EASE trial evaluating the safety and efficacy of Oleogel-S10 in patients with EB.
Highlights
The trial met its
424B3
r4fukfjy4r
31 Jan 22
Prospectus supplement
7:33am
424B3
ixdi291rjuw
31 Jan 22
Prospectus supplement
7:35am
424B4
nf20eq3zo4
14 Jan 21
Prospectus supplement with pricing info
9:30am
424B3
j33xh9z
31 Mar 22
Prospectus supplement
8:44am
424B3
lruue
31 Mar 22
Prospectus supplement
8:44am
F-1
tmt ltjpk
23 Jun 20
Registration statement (foreign)
5:21pm
20-F
128pzt
30 Apr 21
Annual report (foreign)
12:53pm
6-K
EX-99.3
y5x piiev36jx55fhi68
31 Mar 21
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
7:00am
F-1/A
v8i c9w29aeu
12 Jan 21
Registration statement (foreign) (amended)
12:00am
F-1/A
c16e62jmbl5twskmhq
6 Jul 20
Registration statement (foreign) (amended)
5:28pm
DRS
5ofdiejku524cnj4
18 Dec 20
Draft registration statement
12:00am
F-1
3zpeher
8 Jan 21
Registration statement (foreign)
4:58pm
DRS/A
f9eh5 a0v
29 May 20
Draft registration statement (amended)
12:00am
424B4
k75vc
8 Jul 20
Prospectus supplement with pricing info
4:05pm